Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q2 2019 · 10-Q
Revenue$886.00K$886.00K−75.9% vs Q2 2018 Net Income-$49.88M-$49.88MN/M vs Q2 2018 EPS Diluted-$1.21-$1.21N/M vs Q2 2018 Operating Income-$43,600,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$21,619,000N/M Margins · derivedOperating margin-4921.0%−4051.1 pt vs Q2 2018
Net margin-5629.3%−4780.1 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 8, 2019 · 39 d after period end